You can access any of the podium or poster presentations’ abstracts by searching for it below. For the 2026 FIP world congress in Montreal, presentations and summaries from invited speakers are available below, while abstracts are published in the Pharmacy Education Journal (PEJ) here.
Export this Abstract | Print this Abstract |
Add to my preferred Abstracts list |
My preferred Abstracts list (0) |
Back to Search
The safety of febuxostat versus allopurinol in gout patients with hyperuricemia.
- In: Poster presentation
- At: Seoul (South Korea) (2017)
- Type: Poster
- Poster code: POS-HPS-018
- By: CHEN, Jungyi (Kaohsiung Veterans General Hospital, Tainan City, China Taiwan)
- Co-author(s): Jungyi Chen
- Abstract:
Background
The efficacy of Febuxostat is as effective as or more effective than Allopurinol in several evidences. However, FDA had warned that Febuxostat may produce fatal or nonfatal liver failure on November 2012, but the evidence about abnormal liver function was controversial till now.Purpose
To evaluate the safety of Febuxostat included all
.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 23 September 2026